NEUROMEKA CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30,700 KRW | -1.29% |
|
-0.32% | -17.36% |
| 2023 | Neuromeka Co.,Ltd.(KOSDAQ:A348340) added to S&P Global BMI Index | CI |
| 2023 | Neuromeka Participates in FABTECH 2023, Unveiling 3D Vision Collaborative Robot Welding Solution | CI |
Valuation
| Fiscal Period: December | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 1,28,677 | 3,23,322 | - | - |
| Enterprise Value (EV) 1 | 1,28,677 | 3,23,322 | 3,23,322 | 3,23,322 |
| P/E ratio | - | - | - | - |
| Yield | - | - | - | - |
| Capitalization / Revenue | 13.2 x | 12.9 x | 9.51 x | 7.03 x |
| EV / Revenue | 13.2 x | 12.9 x | 9.51 x | 7.03 x |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | 9.73 x | 8.63 x | 7.13 x |
| Nbr of stocks (in thousands) | 10,336 | 10,532 | - | - |
| Reference price 2 | 12,450 | 30,700 | 30,700 | 30,700 |
| Announcement Date | 15/03/23 | - | - | - |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 9.755 | 25 | 34 | 46 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -7.798 | 1 | 5 | 10 |
| Operating Margin | - | -79.94% | 4% | 14.71% | 21.74% |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | -6.594 | -8.201 | - | - | - |
| Net margin | - | -84.07% | - | - | - |
| EPS | -4,581 | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 31/03/22 | 15/03/23 | - | - | - |
1KRW in Billions
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 |
|---|---|
| Net sales 1 | 0.968 |
| EBITDA | - |
| EBIT 1 | -2.529 |
| Operating Margin | -261.25% |
| Earnings before Tax (EBT) | - |
| Net income 1 | -2.185 |
| Net margin | -225.72% |
| EPS 2 | -211.0 |
| Dividend per Share | - |
| Announcement Date | 26/05/23 |
1KRW in Billions2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | 1.3% | 12.1% | 19% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets | - | - | - | - | - |
| Book Value Per Share 1 | - | - | 3,154 | 3,557 | 4,303 |
| Cash Flow per Share 1 | - | - | 454.0 | 1,082 | 1,491 |
| Capex 2 | - | - | 8 | 8 | 8 |
| Capex / Sales | - | - | 32% | 23.53% | 17.39% |
| Announcement Date | 31/03/22 | 15/03/23 | - | - | - |
1KRW2KRW in Billions
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
30,700
KRW
Average target price
53,000
KRW
Spread / Average Target
+72.64%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.36% | 23Cr | |
| +14.78% | 8.75TCr | |
| +9.79% | 6.5TCr | |
| +17.46% | 3.66TCr | |
| +18.60% | 3.29TCr | |
| +0.64% | 2.61TCr | |
| +6.32% | 2.59TCr | |
| -2.61% | 2.51TCr | |
| +17.32% | 2.48TCr | |
| -4.14% | 2.09TCr |
- Stock Market
- Equities
- A348340 Stock
- Financials Neuromeka Co., Ltd.
